Malaria causes the death of 2-3 million people annually, most of these children under 5 years of age. Approximately 300 million cases of acute malaria are reported each year, 90% of these in Africa. Until recently, folate metabolism has been successfully targeted in both prophylaxis and treatment of malaria. Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) is a well defined and validated target for malaria chemotherapy. Unfortunately, resistance to the most commonly used anti-DHFR drugs, including pyrimethamine 1 now limits the clinical usefulness of these drugs
Reference:
Moleele, SS, Gravestock, D, Rousseau, AL and Van Zyl, RL. 2008. Pyrimidines in antimalarial drug designSACI-GDCh Bi-National Organic Chemistry Conference 2008. Incorporating the 10th Frank Warren Conference, Kruger National Park, South Africa, 14-19 September 2008, pp 1
Moleele, S., Gravestock, D., Rousseau, A., & Van Zyl, R. (2008). Pyrimidines in antimalarial drug design. SACI-GDCh Bi-National Organic Chemistry Conference 2008. http://hdl.handle.net/10204/3321
Moleele, SS, D Gravestock, AL Rousseau, and RL Van Zyl. "Pyrimidines in antimalarial drug design." (2008): http://hdl.handle.net/10204/3321
Moleele S, Gravestock D, Rousseau A, Van Zyl R, Pyrimidines in antimalarial drug design; SACI-GDCh Bi-National Organic Chemistry Conference 2008; 2008. http://hdl.handle.net/10204/3321 .
SACI-GDCh Bi-National Organic Chemistry Conference '08 Incorporating the 10th Frank Warren Conference, Kruger National Park, South Africa, 14-19 September 2008
